Organization and Business	9 Months Ended
Sep. 30, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business	Organization and Business Nature of Business Xeris Biopharma Holdings, Inc. ("Xeris," "Xeris Biopharma" or the "Company") is a endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines for serious diseases with significant unmet medical need. Xeris has three commercially available products: Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome; Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous levothyroxine injection for the treatment of hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for Xeris and its partners. Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit (glucagon). The Company relies on a number of single source suppliers and manufacturers for the supply of its products and product candidates.

Organization and Business

9 Months Ended

Sep. 30, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business

Xeris Biopharma Holdings, Inc. ("Xeris," "Xeris Biopharma" or the "Company") is a endocrine and rare disease biopharmaceutical company committed to helping people realize better lives through the development and commercialization of innovative medicines for serious diseases with significant unmet medical need. Xeris has three commercially available products: Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in patients with Cushing’s syndrome; Gvoke, a ready-to-use liquid glucagon for the treatment of severe hypoglycemia; and Keveyis, a proven therapy for primary periodic paralysis. Xeris also has a pipeline of development programs led by XP-8121, a Phase 3-ready, once-weekly subcutaneous levothyroxine injection for the treatment of hypothyroidism, as well as multiple early-stage programs leveraging Xeris’ technology platforms, XeriSol® and XeriJect®, for Xeris and its partners.

Throughout this document, unless otherwise noted, references to Gvoke include Gvoke PFS, Gvoke HypoPen, and Gvoke Kit (glucagon).

The Company relies on a number of single source suppliers and manufacturers for the supply of its products and product candidates.